Business
Vir Biotechnology Announces First Patient Dosed in New Phase 2 Chronic Hepatitis B Virus Trial Evaluating Combinations of VIR-2218, VIR-3434, PEG-IFNα and an NRTI
– STRIVE is the first Phase 2 sub-protocol trial initiated under Vir’s new PREVAIL platform trial investigating the Company’s novel therapies in two chronic
About this update from Vir Biotechnology, Inc.
[{"type":"text","content":"– STRIVE is the first Phase 2 sub-protocol trial initiated under Vir’s new PREVAIL platform trial investigating the Company’s novel therapies in two chronic hepatitis B virus patient populations – SAN FRANCISCO, May 11, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first participant has been dosed in the Phase 2 STRIVE sub-protocol clinical trial evaluating the safety and efficacy of regimens containing combinations of VIR-3434, VIR-2218, pegylated interferon alpha (PEG-IFNα) and a nucleoside reverse transcriptase inhibitor (NRTI) in hepatitis B virus (HBV) immune-active, treatment-naïve adults. The STRIVE sub-protocol trial is the first to initiate under Vir’s new PREVAIL platform trial evaluating VIR-2218 and VIR-3434 with other therapies, including PEG-IFNα and an NRTI, in people at various stages of chronic HBV infection. Initial data from the STRIVE sub-protocol trial are expected in the first half of 2024. “The initiation of our Phase 2 STRIVE sub-protocol trial marks an important clinical milestone in our pursuit of a functional cure for the nearly 300 million people worldwide living with chronic HBV,” said Carey Hwang, M.D., Ph.D., Vir’s Senior Vice President, Clinical Research, Head of Chronic Infection. “The PREVAIL platform trial and its sub-protocol trials uniquely enable the evaluation of our novel investigational medicines in distinct HBV patient populations – those with active viral replication and inflammation and those who are inactive carriers. We’re hopeful that the extensive evaluation of VIR-2218 and VIR-3434 will bring us closer to achieving a functional cure for a broad patient population with chronic HBV infection.” The Company is also enrolling adults who are inactive carriers of HBV in its Phase 2 THRIVE sub-protocol clinical trial. Under the PREVAIL platform trial, the THRIVE sub-protocol trial will evaluate the safety and efficacy of regimens containing VIR-3434 and an NRTI with or without VIR-2218. Initial data from the THRIVE sub-protocol trial are expected in the first half of 2024. VIR-2218 is an investigational subcutaneously administered small interfering ribonucleic acid (siRNA) that has the potential to stimulate an effective immune response and have direct antiviral activity against HBV and hepatitis D virus (HDV). VIR-3434 is an investigational HBsAg...